注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
Syros Pharmaceuticals Inc是一家生物製藥公司。該公司致力於重新保護小分子控制基因表達的能力。該公司致力於開發單一基因突變導致的癌症和疾病的治療方法,也稱為單基因疾病,並建立基因控制醫學的臨床階段管道。該公司的主要候選產品包括Tamibarotene、SY-2101和SY-5609。其他米蛋白是一種選擇性維甲酸受體α(RARα),RAR激動劑陽性的高危骨髓增生異常綜合徵(HR-MDS)和急性髓系白血病(AML)患者。其SY-2101是一種口服形式的三氧化二砷(ATO),用於治療急性早幼粒細胞白血病(APL)。其SY-5609是一種選擇性和有效的口服細胞週期蛋白依賴性激酶7(CDK7)抑製劑,目前正在為某些實體瘤和血癌患者開發。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
Peter Wirth | 71 | 2017 | Independent Chairman |
Nathanael S. Gray | - | 2013 | Scientific Founder & Member of Scientific Advisory Board |
Stefan Knapp | - | 2013 | Member of Scientific Advisory Board |
Richard A. Young | 69 | 2011 | Scientific Founder, Member of Scientific Advisory Board & Director |
Chris Vakoc | - | 2013 | Member of Scientific Advisory Board |
Bradley E. Bernstein | - | - | Member of Scientific Advisory Board |
Mark Murcko | 63 | 2013 | Member of Scientific Advisory Board |
Robert A. Weinberg | - | 2013 | Member of Scientific Advisory Board |
Aviv Regev | 52 | 2013 | Member of Scientific Advisory Board |
Gerard Evan | - | 2013 | Member of Scientific Advisory Board |
Nancy A. Simonian | 62 | 2012 | Director |
Roger D. Tung | 63 | - | Member of Scientific Advisory Board |
Timothy C. Tyson | 70 | 2022 | Independent Director |
Conley Chee | 53 | 2021 | CEO, President & Director |
Marsha H. Fanucci | 69 | 2015 | Independent Director |
Srinivas Akkaraju | 55 | 2017 | Independent Director |
Andrew M. Oh | 52 | 2022 | Independent Director |
Sue Gail Eckhardt | 65 | 2020 | Independent Director |
Deborah Dunsire | 61 | 2021 | Independent Director |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核